283 related articles for article (PubMed ID: 16784020)
1. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Curr Opin Investig Drugs; 2006 Jun; 7(6):501-12. PubMed ID: 16784020
[TBL] [Abstract][Full Text] [Related]
2. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
3. Targeting mTOR for cancer treatment.
Rubio-Viqueira B; Hidalgo M
Adv Exp Med Biol; 2006; 587():309-27. PubMed ID: 17163174
[TBL] [Abstract][Full Text] [Related]
4. [mTOR signal pathway and its inhibitors in antitumor therapy: a review].
Huang JJ; Lin TY
Ai Zheng; 2007 Dec; 26(12):1397-403. PubMed ID: 18076811
[TBL] [Abstract][Full Text] [Related]
5. Mammalian target of rapamycin is a promising target for novel therapeutic strategy against cancer.
Bjelogrlić SK; Srdić T; Radulović S
J BUON; 2006; 11(3):267-76. PubMed ID: 17309148
[TBL] [Abstract][Full Text] [Related]
6. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic.
Huang S; Houghton PJ
Curr Opin Investig Drugs; 2002 Feb; 3(2):295-304. PubMed ID: 12020063
[TBL] [Abstract][Full Text] [Related]
7. PI3K and mTOR inhibitors: a new generation of targeted anticancer agents.
Brachmann S; Fritsch C; Maira SM; García-Echeverría C
Curr Opin Cell Biol; 2009 Apr; 21(2):194-8. PubMed ID: 19201591
[TBL] [Abstract][Full Text] [Related]
8. The biology behind mTOR inhibition in sarcoma.
Wan X; Helman LJ
Oncologist; 2007 Aug; 12(8):1007-18. PubMed ID: 17766661
[TBL] [Abstract][Full Text] [Related]
9. Use of APO2L/TRAIL with mTOR inhibitors in the treatment of glioblastoma multiforme.
Panner A; Parsa AT; Pieper RO
Expert Rev Anticancer Ther; 2006 Sep; 6(9):1313-22. PubMed ID: 17020463
[TBL] [Abstract][Full Text] [Related]
10. The mammalian target of the rapamycin (mTOR) kinase pathway: its role in tumourigenesis and targeted antitumour therapy.
Janus A; Robak T; Smolewski P
Cell Mol Biol Lett; 2005; 10(3):479-98. PubMed ID: 16217558
[TBL] [Abstract][Full Text] [Related]
11. Pharmacodynamic Evaluation of CCI-779, an Inhibitor of mTOR, in Cancer Patients.
Peralba JM; DeGraffenried L; Friedrichs W; Fulcher L; Grünwald V; Weiss G; Hidalgo M
Clin Cancer Res; 2003 Aug; 9(8):2887-92. PubMed ID: 12912932
[TBL] [Abstract][Full Text] [Related]
12. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
13. mTOR kinase inhibitors as a treatment strategy in hematological malignancies.
Grzybowska-Izydorczyk O; Smolewski P
Future Med Chem; 2012 Mar; 4(4):487-504. PubMed ID: 22416776
[TBL] [Abstract][Full Text] [Related]
14. The potential role of mTOR inhibitors in non-small cell lung cancer.
Gridelli C; Maione P; Rossi A
Oncologist; 2008 Feb; 13(2):139-47. PubMed ID: 18305058
[TBL] [Abstract][Full Text] [Related]
15. The mammalian target of rapamycin pathway as a potential target for cancer chemoprevention.
Kopelovich L; Fay JR; Sigman CC; Crowell JA
Cancer Epidemiol Biomarkers Prev; 2007 Jul; 16(7):1330-40. PubMed ID: 17626998
[TBL] [Abstract][Full Text] [Related]
16. mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.
Cejka D; Preusser M; Fuereder T; Sieghart W; Werzowa J; Strommer S; Wacheck V
Anticancer Res; 2008; 28(6A):3801-8. PubMed ID: 19189667
[TBL] [Abstract][Full Text] [Related]
17. The role of mTOR in the management of solid tumors: an overview.
Strimpakos AS; Karapanagiotou EM; Saif MW; Syrigos KN
Cancer Treat Rev; 2009 Apr; 35(2):148-59. PubMed ID: 19013721
[TBL] [Abstract][Full Text] [Related]
18. NVP-BEZ235, a dual PI3K/mTOR inhibitor, prevents PI3K signaling and inhibits the growth of cancer cells with activating PI3K mutations.
Serra V; Markman B; Scaltriti M; Eichhorn PJ; Valero V; Guzman M; Botero ML; Llonch E; Atzori F; Di Cosimo S; Maira M; Garcia-Echeverria C; Parra JL; Arribas J; Baselga J
Cancer Res; 2008 Oct; 68(19):8022-30. PubMed ID: 18829560
[TBL] [Abstract][Full Text] [Related]
19. Hybrid inhibitors of phosphatidylinositol 3-kinase (PI3K) and the mammalian target of rapamycin (mTOR): design, synthesis, and superior antitumor activity of novel wortmannin-rapamycin conjugates.
Ayral-Kaloustian S; Gu J; Lucas J; Cinque M; Gaydos C; Zask A; Chaudhary I; Wang J; Di L; Young M; Ruppen M; Mansour TS; Gibbons JJ; Yu K
J Med Chem; 2010 Jan; 53(1):452-9. PubMed ID: 19928864
[TBL] [Abstract][Full Text] [Related]
20. Aspects of mTOR biology and the use of mTOR inhibitors in non-Hodgkin's lymphoma.
Costa LJ
Cancer Treat Rev; 2007 Feb; 33(1):78-84. PubMed ID: 17161912
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]